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according to Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality 
Index (DLQI) scores. METHODS: All patients who stayed on the same active treat-
ment for 52 weeks were included. Active treatments were subcutaneous secuki-
numab 300 mg (n= 568) or 150 mg (n= 570) at weeks 0, 1, 2, 3, and 4, followed 
by dosing every 4 weeks, and subcutaneous etanercept 50 mg twice weekly for 
12 weeks and then once weekly (n= 323). Total AUCs over the 52-week period by 
percentage of PASI-75/90/100 and DLQI-0/1 (no impact on patient quality of life) 
responders—measuring overall controlled disease time—were determined using 
all responder numbers at all scheduled visits. RESULTS: Total AUCs for patients 
who received secukinumab 300 and 150 mg, and etanercept, respectively, were: 
3857.8, 3286.9, and 2628.1 (PASI-75); 3017.7, 2212.2, and 1531.8 (PASI-90); 1677.0, 
978.9, and 452.5 (PASI-100); and 3029.8, 2492.2, and 1991.4 (DLQI-0/1). Total AUC 
ratios for secukinumab 300 and 150 mg, respectively, vs etanercept were 1.47 and 
1.25 (PASI-75); 1.97 and 1.44 (PASI-90); 3.71 and 2.16 (PASI-100); and 1.52 and 1.25 
(DLQI-0/1). Total AUC ratios for secukinumab 300 vs 150 mg were 1.17 (PASI-75), 
1.36 (PASI-90), 1.71 (PASI-100), and 1.22 (DLQI-0/1). CONCLUSIONS: In patients with 
moderate-severe plaque psoriasis, greater AUCs by PASI-75/90/100 and DLQI-0/1 
responders were achieved with secukinumab 300 mg, followed by secukinumab 
150 mg and etanercept. This analysis suggests that secukinumab 300 mg resulted 
in the best overall disease control over time.
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OBJECTIVES: The aim of this study was to assess the knowledge and practice 
of International Islamic University Malaysia (IIUM) Kuantan Undergraduate 
Pharmacy students on the use of skin whitening product. METHODS: A self-
administered questionnaire on the use of skin whitening product was dis-
tributed to IIUM Kuantan Undergraduate Pharmacy students at IIUM Kuantan 
Malaysia. RESULTS: Three hundred and nine (309) of four hundred (400) students 
responded (77% response rate). The highest percentage of participants is from 
year three students which is 33.3% while year four students are the least which 
is 18.8%. The mean of knowledge score, regardless of their year of study is 6.75 
over 14. Among the user and non-user of skin whitening products, user shows 
higher mean knowledge score which is 7.5041 than non-user which is 6.2527.Of 
the participants, 39.8% (123/309) are using the skin whitening products. 90.8% 
(108/119) of the respondent read the instruction of the products before using 
them. CONCLUSIONS: It is proven that the user of skin whitening products has 
better knowledge about the product than the non-user. Half of the participants 
are still practicing poor practice in using the skin whitening products. There is a 
need to educate the students about the proper usage of skin whitening products 
to avoid any misuse of these products.
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OBJECTIVES: Characterize baseline utilization of antidepressant and psychotropic 
medications in older adults with age-related macular degeneration (AMD) and 
depressive symptoms. METHODS: Patients ≥ 65 years with bilateral AMD and 
subthreshold depressive symptoms were recruited from a large private retina 
practice affiliated with a tertiary eye care institution to participate in the Low 
Vision Depression Prevention Trial testing a multi-component intervention that 
combined low vision rehabilitation (LVR), home-based occupational therapy, and 
behavioral activation versus supportive therapy with LVR. Variables considered 
were age, sex, race, education, marital status, living situation, medical comorbid-
ity, depressive symptoms, and medication use. Medications of interest included 
prescription antidepressants and psychotropics. Depressive symptoms were meas-
ured using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 1 to 27, 
with higher scores indicating greater severity. Scores ≥ 5 indicate at least mild 
depression. RESULTS: Of the 188 participants, 70% were female, 98% Caucasian, 
and the mean age was 84. The mean PHQ-9 score was 5.5 (SD 2.3), and 32% were 
taking at least one depression and/or psychotropic medication. For those reporting 
these medications, 47 (25%) reported 1 medication, 12 (6%) reported 2 medications, 
and one (0.05%) reported 3 medications. Participants with higher PHQ-9 scores 
were more likely to report ≥ 1 depression and/or psychotropic medication (p = 
0.001). No significant associations were found between use of these medications 
and demographic or medical variables with the exception of cardiovascular dis-
ease (p = 0.033). CONCLUSIONS: Individuals with AMD are at risk for depressive 
disorders due to the substantial impact vision loss has on quality of life. In this 
study, about one third of patients reported depression and/or psychotropic medi-
cation treatment. While this rate is higher than prior studies, findings suggest an 
opportunity to increase the number treated with medications and/or behavioral 
approaches.
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OBJECTIVES: Acne vulgaris is described as a common skin disease involving block-
age and inflammation of pilosebaceous unit such as hair follicles and sebaceous 
gland. As many factors may contribute to the formation of acne, this study attempt 
(70.4%). Approximately 6,270 (12.7%) had a coded AE. Of the AE patients, 3.2% were 
persistent with treatment despite the AE, 7.4% switched to another treatment within 
8.8 days, and 89.4% discontinued therapy within 31.1 days. AE patients incurred $325 
(medical: $143, pharmacy: $182) in rosacea-related costs, while patients without AEs 
incurred $172 (medical: $14, pharmacy: $157). CONCLUSIONS: The majority of AEs 
associated with current rosacea drugs/formulations resulted in treatment switch/
discontinuation. New drug/formulation may provide additional treatment options 
for patients with AEs and lead to improved persistence and better symptom control.
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OBJECTIVES: To undertake a network meta-analysis (NMA) to assess the effective-
ness of licensed interventions (aflibercept 2q8, ranibizumab PRN, pegaptanib and 
photodynamic therapy (PDT)) in the treatment of neovascular (wet) age-related 
macular degeneration (wet AMD). METHODS: A systematic review was undertaken 
to identify trials comparing any of the interventions to treat neovascular AMD 
reporting change in best corrected visual acuity (BCVA). A NMA of the studies was 
carried out using WinBugs. Identified studies often reported results at multiple time 
points. Hence, a number of models were applied accounting for the time structure 
in the data. The deviance information criterion (DIC) was used to select the most 
appropriate model. Multiple separate networks were applied to the data to account 
for the fact that posologies were equivalent at some time points. RESULTS: 21 tri-
als were included in the network. Aflibercept and ranibizumab were found to be 
statistically superior to PDT and pegaptanib at 12 and 24 months. The mean change 
from baseline BVCA estimated between ranibizumab and PDT at 12 months was 
18.85 [15.42 to 22.26] and at 24 months was 20.62 [17.25 to 23.96]. The mean change 
from baseline BVCA estimated between ranibizumab and pegaptanib at 12 months 
was 11.16 [2.93, 20.63] and at 24 months was 11.71 [3.31, 25.06]. Results for afliber-
cept were quantitatively similar. There was minimal difference in the effectiveness 
of ranibizumab and aflibercept at any time point: mean difference at 12 months 
numerically favoured ranibizumab by 0.05 [-1.33 to 1.52] and at 24 months by 0.02 
[-1.36 to 1.44]. CONCLUSIONS: Aflibercept and ranibizumab are effective treatments 
for neovascular AMD demonstrating a clinically and statistically significant differ-
ence in BVCA compared with PDT and Pegaptanib. There were only minimal (non-
statistically significant) differences in the relative effectiveness of aflibercept and 
ranibizumab at any time point.
PSS3
comParative effectiveneSS of bimatoProSt 0.03%/timolol 0.5% 
PreServative-free fixed combination for the treatment of oPen-
angle glaucoma and oht; interPreting reSultS from a large 
treatment networK
Saunders O.1, Wong W.2, Collomb D.3, Stradwick S.1
1BresMed, Sheffield, UK, 2Allergan Inc, Irvine, CA, USA, 3Allergan Ltd, Marlow, UK
OBJECTIVES: A network meta-analysis (NMA) evaluating the effectiveness of 
bimatoprost 0.03%/timolol 0.5% preservative-free (PF) fixed combination (PF 
BTFC) solution in single-dose vials for the treatment of glaucoma/ocular hyper-
tension (OHT) compared to alternative therapies has been updated (Harvey et 
al 2013). The outcome of interest was change from baseline (CFB) in intraocular 
pressure (IOP). METHODS: Systematic searches originally conducted in October 
2012 were updated to identify additional randomized controlled trials investigat-
ing the efficacy of glaucoma/OHT therapies, where efficacy is defined as IOP CFB. 
A Bayesian model with random effects for trial, week and time of day was fitted 
to synthesize the resulting evidence base. RESULTS: In total, 170 studies met 
the pre-determined mixed treatment comparison inclusion criteria, represent-
ing 34 unique treatment arms. PF BTFC was numerically superior to all treat-
ments (monotherapies and combination therapies; preserved and PF therapies) 
in lowering IOP and statistically significant (p< 0.05) for all but seven of the 33 
comparisons. Furthermore, despite some trials being adequately sized and the 
treatment effect showing similar levels of uncertainty to others in the network, 
the credible intervals (CI) for these treatments were among the widest in the 
network. CONCLUSIONS: PF BTFC was numerically but not statistically superior 
to all treatments in lowering IOP. The sample size required to show statistically 
significant results in NMAs is larger than for head-to-head randomized trials 
because the precision of comparisons made across a network is proportional not 
only to the size and uncertainty of individual trials but also to the number of nodes 
separating treatments (Thorlund 2012). This is thought to be a key driver of the 
width of CIs for some treatments within this network. Results from the updated 
NMA will be presented along with a discussion of the interpretation of results for 
large and complex networks.
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OBJECTIVES: Assessment of how therapies achieve cumulative disease control 
over time is critical. In two phase III, 52-week trials (ERASURE and FIXTURE), 
secukinumab—a human, anti–interleukin-17A, monoclonal antibody—was an 
effective treatment for moderate-severe chronic plaque psoriasis. Pooled analysis 
of these trials was performed to explore the cumulative efficacy of secukinumab 
by assessing area-under-the-curve (AUC) of percentage of treatment responders 
